Pharming Receives U.K. Approval For Joenja In Children Aged 4 To 11 With APDS, Supported By Pediatric Clinical Program Data; Marks Step In Expansion Across Age Groups And Markets
Benzinga Newsdesk 21 hours ago
News
Approval extends existing U.K. indication for Joenja to eligible children aged 4 to 11 who weigh at least 27 kgJoenja is expected to become available to patients covered by the expanded indication in February 2027Marks
- Approval extends existing U.K. indication for Joenja to eligible children aged 4 to 11 who weigh at least 27 kg
- Joenja is expected to become available to patients covered by the expanded indication in February 2027
- Marks another step in Pharming’s strategy to expand Joenja across age groups and international markets